Comment from Jason Begalke
AnonymousSupportIndividual
Summary: Dr. Jason J. Begalke supports the Haystack Project's petition to modernize FDA regulatory frameworks for rare diseases. He argues that the current reliance on large-scale randomized controlled trials is unsuitable for small patient populations and advocates for context-driven evidence like natural history controls and disease-specific endpoints.
Beyond the RCT: Why the FDA Must Modernize for Rare Biology<br/>Our regulatory framework suffers from a profound methodological bias. It treats the randomized controlled trial (RCT) as an absolute scientific truth, rather than what it actually is: a tool built for high-volume, mass-market data.<br/>For the 30 million Americans living with a rare or ultra-rare condition, this "one-size-fits-all" standard is mathematically and logistically impossible. When a total global patient population is measured in dozens, demanding large-scale placebo arms isn't just a hurdle—it is an anatomical mismatch.<br/>The Citizen Petition submitted to the FDA by the Haystack Project addresses this exact structural flaw. Backed by a coalition of over 160 advocacy groups, the petition pushes for a legally binding, context-driven framework that aligns regulatory review with modern clinical science. <br/>The Science of Small Data<br/>Moving beyond the traditional RCT does not mean lowering the evidentiary bar. It means embracing advanced, fit-for-purpose evidence generation tailored to complex biology: <br/> Natural History Controls: Utilizing high-fidelity, longitudinal patient registries to serve as virtual comparator arms, eliminating the ethical and logistical challenges of standard placebos.<br/> Disease-Specific, "Clinically Meaningful" Endpoints: Moving past rigid, countable metrics designed for common chronic conditions (like general seizure tallies) and focusing on multi-sensory or functional biomarkers that truly reflect a patient's quality of life.<br/> Formalized Disease Expertise: Structuralizing the role of disease-specific scientists, clinicians, and patient representatives directly within the FDA's decision-making process to evaluate targeted novel mechanics, like emerging cell and gene therapies. <br/>We are entering a historic era of precision medicine, yet our regulatory pathways remain stagnant, trapped in a bygone statistical paradigm. Capital and biotech innovation follow regulatory certainty; without clear, modern rules, investment in ultra-rare conditions will stall. <br/>The Haystack Project's petition is a vital step toward a more sophisticated, scientifically grounded framework. The metrics we use to judge efficacy must be as precise and adaptive as the science used to create the cure. - Dr. Jason J. Begalke